Antithrombotic strategy | Major bleeding events | ||
---|---|---|---|
Annual incidence rate | Adjusted HR (95%CI) | P value | |
Any OACs cohort | |||
CHA2DS2-VASc of 0–1 | |||
- OACs | 0.97 (0.36–2.11) | 11.37 (0.95-135.37) | 0.054 |
- No OACs | 0.15 (0.01–0.82) | Reference | |
CHA2DS2-VASc of 2 or more | |||
- OACs | 2.68 (2.23–3.18) | 2.29 (1.26–4.14) | 0.006* |
- No OACs | 1.56 (0.93–2.47) | Reference | |
Warfarin cohort | |||
CHA2DS2-VASc of 0–1 | |||
- Warfarin | 1.16 (0.42–2.51) | 13.69 (1.18–159.40) | 0.037* |
- No OACs | 0.15 (0.01–0.82) | Reference | |
CHA2DS2-VASc of 2 or more | |||
- Warfarin | 2.77 (2.30–3.31) | 2.38 (1.32–4.32) | 0.004* |
- No OACs | 1.56 (0.93–2.47) | Reference | |
DOACs cohort | |||
CHA2DS2-VASc of 0–1 | |||
- DOACs | - | - | - |
- No OACs | 0.15 (0.01–0.82) | Reference | |
CHA2DS2-VASc of 2 or more | |||
- DOACs | 1.60 (0.60–3.53) | 3.62 (0.88–14.80) | 0.074 |
- No OACs | 1.56 (0.93–2.47) | Reference |